On September 23, 2019 Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, reported that Eric Poma, Ph.D., Chief Executive Officer and Chief Scientific Officer, will present a corporate overview at the Ladenburg Thalmann 2019 Healthcare Conference, and the Cantor Fitzgerald 2019 Healthcare Conference, both taking place in New York City (Press release, Molecular Templates, SEP 23, 2019, View Source [SID1234539703]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ladenburg Thalmann 2019 Healthcare Conference
Date: Tuesday, September 24
Time: 10:00am Eastern Time
Webcast: View Source

Cantor Fitzgerald 2019 Healthcare Conference
Date: Friday, October 4
Time: 12:00pm Eastern Time
Webcast: View Source

On September 23, 2019 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported that it will host an investor and analyst event on Friday, October 4, 2019 from 8:00 a.m. to 11:30 a.m. ET in New York City, entitled "A New Chapter in PI3Kδ Inhibition to Treat B-cell Malignancies (Press release, MEI Pharma, SEP 23, 2019, View Source [SID1234539702])."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The agenda will include an in-depth review of the PI3K pathway, an overview of the B-cell malignancy treatment landscape, and an update on the MEI Pharma pipeline with a focus on ME-401, a differentiated inhibitor of PI3Kδ.

The event will also feature key opinion leaders in PI3K inhibition and the treatment of B-cell malignancies, including guest speakers:

Lewis C. Cantley, Ph.D.
Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College, Professor of Cancer Biology in Medicine
Nishitha M. Reddy, M.D., M.B.B.S.
Associate Professor of Medicine at Vanderbilt University Medical Center
Matthew J. Matasar, M.D.
Medical Director, Memorial Sloan Kettering Bergen
Webcast Information
You can access the live webcast under the investor relations section of MEI’s website on the "Events and Presentation" page at: www.meipharma.com. A replay of the webcast will be archived for at least 30 days after the conclusion of the live event.

On September 23, 2019 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, reported that preliminary results from its ongoing Phase 2 basket trial, evaluating DPX-Survivac in combination with Merck’s Keytruda (pembrolizumab) and intermittent low dose cyclophosphamide (CPA) in patients with advanced and metastatic solid tumors, will be presented during the Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) poster session at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2019 Congress, being held September 27 – October 1, 2019, in Barcelona, Spain (Press release, IMV, SEP 23, 2019, View Source [SID1234539701]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Poster Title: "Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours (preliminary results)"

Presenter: Henry J Conter, M.D., Medical Oncology Director, William Osler Cancer Centre Date and Time: Sept. 30, 2019, 12:00-13:00 CEST – poster will be displayed all day

Abstract Number: 1208P
Session Title: Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)
Poster Display: Session 3, Poster Area – Hall 4

ESMO has published the official abstracts on its meeting website in advance of the ESMO (Free ESMO Whitepaper) Annual Meeting at 00:05 CEST on Sept. 23rd, 2019. The cut-off date for inclusion of data in the abstract was August 21st, 2019.

About the Phase 2 Basket Trial

IMV’s Phase 2 basket trial is an open label, multi-center study, evaluating DPX-Survivac across five cohorts of patients with bladder cancer, liver cancer (hepatocellular carcinoma), ovarian cancer, non-small cell lung cancer (NSCLC) and tumors shown to be positive for the microsatellite instability high (MSI-H) biomarker.

Subjects will receive DPX-Survivac (SC: 2 x 0.25 mL every three weeks, followed by up to 11 x 0.1 mL every nine weeks), in combination with pembrolizumab (IV: 200 mg every 3 weeks cycle)

and CPA (oral: 50 mg BID on alternating weeks) across the five cohorts. The study is designed to assess primary endpoints of safety and objective response rate (ORR), with multiple secondary and exploratory measures.

The study included a safety lead-in, which included 20 patients from all five cohorts. The five cohorts are now expanded to recruit additional subjects following a Simon two stage design. Enrollment in the ovarian cancer cohort will be randomized 1:1 into two arms with and without CPA. All other cohorts will utilize a single-arm design and administer treatment with the triple combination. IMV expects to enroll 184 patients across clinical sites in the U.S. and Canada.

About DPX-Survivac

DPX-Survivac is the lead candidate in IMV’s new class of immunotherapies that programs targeted T cells in vivo. It has demonstrated the potential for industry-leading targeted, persistent, and durable T cell activation. IMV believes this mechanism of action (MOA) is key to generating durable solid tumor regressions. DPX-Survivac consists of survivin-based peptides formulated in IMV’s proprietary DPX drug delivery platform. DPX-Survivac is designed to work by eliciting a cytotoxic T cell immune response against cancer cells presenting survivin peptides on their surface.

Survivin, recognized by the National Cancer Institute (NCI) as a promising tumor-associated antigen, is broadly over-expressed in most cancer types, and plays an essential role in antagonizing cell death, supporting tumor-associated angiogenesis, and promoting resistance to chemotherapies. IMV has identified over 20 cancer indications in which survivin can be targeted by DPX-Survivac.

DPX-Survivac has received Fast Track designation from the U.S. Food and Drug Administration (FDA) as maintenance therapy in advanced ovarian cancer, as well as orphan drug designation status from the U.S. FDA and the European Medicines Agency (EMA) in the ovarian cancer indication.

On September 23, 2019 Immune Therapeutics, Inc. (OTC: IMUN) (IMUN) ("Immune" "IMUN" or the "Company"), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment of autoimmune and inflammatory conditions, cancer, HIV/AIDS and animal diseases on a global basis is reported the appointment of Michael K. Handley as the new Chief Executive Officer of Immune Therapeutics’ and Member of the Board of Directors (Press release, Immune Therapeutics, SEP 23, 2019, View Source [SID1234539700]). IMUN also announces the resignation of its former CEO, and Director, Noreen Griffin.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Handley maintains an extensive background in the life science sector, dating back over two decades with cross-functional experience in product commercialization, regulatory and clinical affairs, operations, mergers and acquisitions, financing, market development and partnering/licensing. He has founded multiple health industry enterprises and held executive, management and advisory positions in a substantial number of leading public and private pharmaceutical and biotechnology companies. Mr. Handley retains an expansive history in drug development with multiple patents and peer-reviewed publications in the areas of oncology, anti-infectives, inflammation and neuroscience. He has assisted or led in the global commercialization of seventeen products that account for over six billion dollars in sales annually and has secured millions of dollars in private equity and venture capital for numerous high growth organizations.

"We are pleased to welcome Michael Handley, a highly regarded professional in our field, and believe he is a good fit with our development strategy and look forward to benefiting from his extensive experience and perspective. Mr. Handley is a distinguished Pharmaceutical Executive who adds a vast degree of knowledge and experience to Immune Therapeutics as we restructure and move forward with the development and commercialization of our pipeline of immunotherapies."" stated Dr. Roscoe Moore, Jr. DVM, MPH, PhD Former Assist US Surgeon Gen (retired)., Chairman of the Board, Immune Therapeutics. Dr. Moore Jr. added, "On behalf of the Immune Therapeutics Board of Directors, I would also like to thank Ms. Griffin for her contributions during the five years that she has led Immune Therapeutics, Inc."

Mr. Handley is currently the Chief Executive Officer and Chairman at Aletheia Therapeutics Corp. a private biopharmaceutical company focused on the development and commercialization of therapies for the treatment of cancer. Additionally, he holds board positions at Medavate Corp. and Symbios Technologies, Inc. He has held leadership positions at Johnson & Johnson and Amgen, as well as Genentech, where he assisted in the launch of Avastin & Tarceva. Mr. Handley retained numerous roles in an Executive capacity that contribute to his seasoned global expertise in the drug development arena including former Chief Executive Officer and Director at Armis Biopharma, Inc., Vice President of Quality, Clinical and Regulatory Affairs at Vessix Vascular, Inc. (acquired by Boston Scientific), Chief Compliance Officer and Vice President of Global Regulatory Affairs at The Spectranetics Corporation (acquired by Phillips) and Executive Affiliate/Senior Principal for the management-consulting firm Pittiglio Rabin Todd & McGrath (acquired by PricewaterhouseCoopers). In addition to a multitude of other healthcare positions, Mr. Handley graduated from Colorado State University with degrees in Biology and Physiology and minors in chemistry and neuroanatomy. He also attended the executive MBA program at the Graziadio School of Business and Management at Pepperdine University.

"Michael Handley has had a distinguished career as a successful drug developer in the biopharmaceutical industry with expertise in leading clinical strategy, design and management of novel oncology and inflammatory programs, experience that aligns perfectly with our goal to bring our T-Cell Activation therapies to patients in need," said Noreen Griffin, former Chief Executive Officer and Director, Immune Therapeutics. "Mike brings to Immune Therapeutics significant business development and strategy experience, perfectly suited to help us maximize the opportunities we see with our platform. On behalf of the entire team, I want to welcome Michael K. Handley and we look forward to his leadership and contributions."

"I am excited to be joining Immune Therapeutics and leading the effort to develop and commercialize the next generation of immunotherapies" said Mr. Handley. "I believe there is an opportunity to fundamentally change the way we treat cancer and other disease states by using new agents that target the activity of the human immune system."

On September 23, 2019 Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX) reported that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 2019 Cantor Global Healthcare Conference as follows (Press release, Eagle Pharmaceuticals, SEP 23, 2019, View Source [SID1234539699]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, October 2, 2019
Time: 7:45 a.m. Eastern Daylight Time
Location: Intercontinental New York Barclay Hotel, NYC
Webcast: View Source

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors + News Section.